AbbVie Inc. ranks below the peer group median, with a split structural profile: strong stability, but weak profitability and valuation. Recent price action is broadly in line with the structural positioning.
Peer-relative scores, weakest to strongest
AbbVie Inc. develops and markets pharmaceutical products, focusing on immunology and specialty therapies. The company has blockbuster drugs and an ongoing pipeline.
The market prices AbbVie based on renewal risk rather than sustainable earnings power, unlike its more stable peers. Despite 12.4% revenue growth in Q1 2026, the 55% decline in legacy Humira sales is only partially offset by new immunology therapies, so AbbVie is considered a transition case rather than a steady compounder. With ROIC at 8.2%, AbbVie is below the peer median, and the market discounts its valuation due to heightened sensitivity to biosimilar competition and regulatory risks for high-cost specialty drugs—factors that drive greater volatility in investor expectations compared to more insulated biopharma peers. Instead of rewarding AbbVie with a defensive quality premium, the market applies a valuation discount that reflects its perceived fragility and exposure to sector-specific risks. The market will re-rate AbbVie in line with peers only if Skyrizi and Rinvoq sustain double-digit growth and reduce dependence on blockbusters.
Break down ABBV's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.